In a study by Xiao et al., HER-2/neu overexpression had significant association with higher clinical stage (III-IV), lymph node metastasis, and tumors at the G23 phase, but there was no association with age of the patient and depth of invasion (15). Here, ERBB2 is linked to metastatic malignant neoplasm in the lymph nodes.